Rigel Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $117.2 Mil.
Warning Sign:
If a company builds assets at 32.2% a year, faster than its revenue growth rate of 21.3% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Rigel Pharmaceuticals's average Total Assets Growth Rate was -20.70% per year.
During the past 3 years, the average Total Assets Growth Rate was 4.40% per year.
During the past 5 years, the average Total Assets Growth Rate was 32.20% per year.
During the past 10 years, the average Total Assets Growth Rate was 30.60% per year.
During the past 13 years, Rigel Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 150.90%. The lowest was -37.90%. And the median was 2.40%.
Rigel Pharmaceuticals Total Assets Historical Data
The historical data trend for Rigel Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Rigel Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rigel Pharmaceuticals (NAS:RIGL) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Rigel Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Rigel Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Rigel Pharmaceuticals (Rigel Pharmaceuticals) Business Description
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
RIGL has been successfully added to your 